Drug Profile
Research programme: urinary tract infections therapeutics - Fimbrion Therapeutics
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Fimbrion Therapeutics
- Developer Fimbrion Therapeutics; GSK
- Class Small molecules
- Mechanism of Action Cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Urinary tract infections
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Urinary-tract-infections in United Kingdom (PO)
- 28 Nov 2020 No recent reports of development identified for research development in Urinary-tract-infections in USA (PO)
- 28 Nov 2020 No recent reports of development identified for research development in Urinary-tract-infections(Prevention) in United Kingdom (PO)